A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Exclusion Criteria

• •Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
• •Exacerbation of underlying lung disease within 28 days prior to randomization.
• •Initiation of pulmonary rehabilitation within 28 days prior to randomization.
• •Receiving \>10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
• •History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.
• •Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.